Inhibrx Biosciences: Cruising Toward FDA Approval, But Getting Ahead Of Itself
Source: SeekingAlpha
2025-10-27 10:01:28 ET
Topline Summary And Update
I've looked at Inhibrx Biosciences ( INBX ) a few times now, first with optimism at $15 per share and then growing more muted after the share price had more than doubled earlier this year. As of my last article, I have a "Hold" rating coming into Q4, with a feeling that there would be a better entry point in terms of share price after a meteoric rise....
Read the full article on Seeking Alpha
For further details see:
Inhibrx Biosciences: Cruising Toward FDA Approval, But Getting Ahead Of Itself
Inhibrx Biosciences Inc.
NASDAQ: INBX
INBX Trading
5.11% G/L:
$73.67 Last:
58,921 Volume:
$72.19 Open:
INBX Latest News
INBX Stock Data
$1,212,947,749
8,822,231
0.71%
112
N/A
Biotechnology & Life Sciences
Healthcare
US
La Jolla
